A two-year longitudinal follow-up of cognitive performance assessed by BICAMS in newly diagnosed patients with MS by Skorve, Ellen et al.
Contents lists available at ScienceDirect
Multiple Sclerosis and Related Disorders
journal homepage: www.elsevier.com/locate/msard
Original article
A two-year longitudinal follow-up of cognitive performance assessed by
BICAMS in newly diagnosed patients with MS
Ellen Skorvea,b,⁎, Astri J. Lundervoldc, Øivind Torkildsena,b, Kjell-Morten Myhrb
aNeuro-SysMed, Department of Neurology, Haukeland University Hospital, Bergen, Norway
bDepartment of Clinical Medicine, University of Bergen, Bergen, Norway
c Department of Biological and Medical Psychology, University of Bergen, Bergen, Norway







A B S T R A C T
Background: : Cognitive impairment is common in patients with multiple sclerosis (MS) and may occur at any
stage and with any subtype of the disease. Screening and monitoring of cognitive function should therefore be
implemented into everyday clinical neurology practice. The Brief International Cognitive Assessment for
Multiple Sclerosis (BICAMS) was developed for this purpose. Although several cross-sectional studies have va-
lidated BICAMS, longitudinal studies evaluating its use as part of a clinical follow-up routine are still lacking.
Objective: : To investigate cognitive function and trajectories of change assessed by the BICAMS test battery in a
cohort of newly diagnosed relapsing-remitting MS (RRMS) patients examined at baseline and after 12 and 24
months.
Methods: : BICAMS was used to assess cognitive function in 58 RRMS patients, who also filled in the Hospital
Anxiety and Depression Scale (HADS) and the Fatigue Scale for Motor and Cognitive Functions (FSMC), and
underwent standard neurological evaluations at baseline and at the two follow-ups.
Results: : A total of 27 patients (46.6%) were defined as cognitively impaired at baseline on at least one test, and
22 (37.9%) were defined as impaired at follow-up after 24 months. Throughout the study, 8 (13.8%) and 4
(6.9%) patients were consistently defined as impaired on two or three tests, respectively. The mean raw scores
on two BICAMS subtests (SDMT and CVLT-II) improved significantly from baseline to the first follow-up, and
then remained stable the next year, whereas the visual memory test (BVMT-R) were overall unchanged from
baseline to the end of the study. The correlations between the scores on HADS, FSMC and the BICAMS subtests
were non-significant at baseline, but weak to moderate negative correlations were found at the one- and two-
year follow-ups.
Conclusion: : The patients showed improved test results from baseline to the first follow-up examination, in-
dicating that an effect of previous practise should be taken into account when interpreting the results. With
results showing both trajectories of stability and change, our study supported the validity of including BICAMS
as part of a clinical follow-up routine of RRMS patients. Anxiety, depression, fatigue and cognition should always
be assessed at the same time to reveal interaction effects that are expected to affect the daily-life functioning of at
least some of the RRMS patients.
1. Introduction
Multiple sclerosis (MS) is a chronic inflammatory disease of the
central nervous system affecting mainly young adults (Thompson et al.,
2018). Without therapy, most patients will eventually develop severe
disability. Increasingly more effective therapies have become available
to reduce disease activity and minimize the neurological symptoms
associated with the disease (Dobson and Giovannoni, 2019;
Torkildsen et al., 2016). Still, many patients experience impairment of
cognitive and emotional functions (Whitehouse et al., 2019).
Cognitive impairment in patients with MS may be present from the
early stages of the disease course (Amato et al., 2001, 2006;
Bobholz and Rao, 2003; Chiaravalloti and DeLuca, 2008; Cortese et al.,
2016), and represents an economic and social burden on the individual
as well as the society, mainly due to loss of work capacity and latency of
work place customization. An international effort has therefore been
put into the work to validate and standardize clinical routines including
assessment of cognitive function. The Brief International Cognitive
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Assessment for Multiple Sclerosis (BICAMS) is an outcome from this
work (Benedict et al., 2012; Langdon et al., 2012). Several cross-sec-
tional studies have shown that the BICAMS is a reliable and valid test
battery to identify cognitive impairment in patients with MS
(Corfield and Langdon, 2018), and we have recently reported that al-
most 50% of newly diagnosed patients with MS had some degree of
cognitive impairment measured by the BICAMS (Skorve et al., 2019).
The aim of the current study was to investigate cognitive perfor-
mance in a sample of newly diagnosed patients with MS using the
BICAMS test battery in a two-year longitudinal study. Although some
recent studies present longitudinal data on cognitive impairment in MS-
patients (Barbu et al., 2018; Berard et al., 2018; Damasceno et al., 2019;
Healy et al., 2020; Katsari et al., 2020), few studies have presented
results from repeated assessment with the BICAMS subtests over longer
intervals (Frau et al., 2018; Jakimovski et al., 2019), and none with
cognitive evaluation as primary focus. Therefore, this study is probably
the first longitudinal study to evaluate the results on the BICAMS
subtests in a sample of newly diagnosed patients, and will by this
contribute to evaluate if the test battery should be included in a clinical
follow-up routine of patients with MS from an early stage of the disease.
2. Methods
2.1. Study population
BICAMS was used to evaluate cognitive function in a sample of 58
patients with relapsing-remitting MS (RRMS) and less than two years
mean disease duration. Baseline data were recently published
(Skorve et al., 2019) and in this paper we present follow-up data from
evaluations after 12 and 24 months.
2.2. Procedures
Participation in the study was based on written informed consent,
and the study was approved by the Regional Ethics Committee of
Western Norway (registration number 2016/31/REK Vest)
The patients did not receive any economic compensation for their
participation other than follow-up appointments free of charge during
the study. All clinical and cognitive tests were performed by a clinical
neurologist (E.S).
2.2.1. Questionnaires (Norwegian translations)
Symptoms of depression and anxiety were assessed at each test
session by self-reports on the Hospital Anxiety and Depression Scale
(HADS) (Pais-Ribeiro et al., 2018; Zigmond and Snaith, 1983). A score
of ≥8 on each of the HADS sub scores were used to define a clinically
meaningful anxiety or depression disorder (Bjelland et al., 2002;
Dahl et al., 2009). Prevalence of fatigue were assessed by self-reports on
the Fatigue Scale for Motor and Cognitive Functions (FSMC), and the
combined score of ≥43 was used as the cut-off to define MS-related
fatigue (Penner et al., 2009). A self-report questionnaire listing their
education and employment status were also completed at each test
session.
2.2.2. Clinical evaluations
All participants underwent a standard neurological status ex-
amination, including scoring of the Expanded Disability Status Scale
(EDSS) (Kurtzke, 1983).
2.2.3. Neuropsychological tests: BICAMS
The oral version of the Symbol Digit Modalities Test (SDMT)
(Smith, 1982) was included as a measure of information processing
speed both at baseline and the follow-up sessions. No alternative stimuli
was included, as studies have shown only minor learning effects and a
high test-retest reliability of SDMT (Strober et al., 2009). The initial
learning trials of the official Norwegian translation of the 2nd edition of
the California Verbal Learning Test (CVLT-II) (Delis et al., 1987) was
included as a measure of verbal memory function. To reduce the risk of
a learning effect, known to be significant from baseline to the first
follow-up session (Lundervold et al., 2014), an alternative list of 16
words was included in the second assessment procedure. This alter-
native list included the words from the interference list of the standard
format of CVLT-II (List B) as this list was not presented as part of the
first test session and have a similar construction as the original list. The
word list (List A) from the baseline session was then reintroduced as
part of the second follow-up session at 24 months. The initial learning
trials of the BVMT-R (Benedict, 1997) were included as a measure of
visual memory function. Due to a potential learning effect, the test
stimuli were different at baseline and the follow-up sessions (Form 1,
Form 2 and Form 3, respectively). A test score was defined as abnormal
if the score was ≥1.5 standard deviation below the mean in a control
group examined in a previous study (Skorve et al., 2019).
2.3. Statistical analyses
Statistical analyses were performed using SPSS version 24 (IBM
Corp., Armonk, NY), and figures were made using StataSE version 16
(StataCorp LLC, College Station, Texas). Statistical significance was set
at alpha level <0.05. Within-group differences were examined with
student's paired samples t-test and McNemar test for continuous and
categorical variables, respectively. Effect sizes were calculated and




The sample included 58 RRMS patients (18 men, 44 women) with
mean age of 37.6 (± 10.6) years at baseline and mean disease duration
of 1.9 (± 1.3) years since onset of the first symptom (range 0.3–5.3)
and 1.2 (± 0.8) years since diagnosis (range 0.2–2.7). Most (89.5%) of
the patients were employed at baseline, and 83.9% were still employed
at the last follow-up (p = 0.39).
3.2. Clinical characteristics
Median EDSS was 1.5 and remained stable throughout the study
duration. No significant changes were observed for the EDSS (p= 0.11)
or the mean HADS (p = 0.78) scores from baseline to 24 months
(Table 1). Both fatigue sub-scores (motor and cognitive) showed a
significant worsening from baseline to 12 months (p = 0.021, and
p = 0.025, respectively), but only the motor score showed significant
overall worsening from baseline to 24 months (p = 0.028) (Table 1).
At baseline, 93.1% of the patients received disease modifying
therapy (DMT), and 98.3% were on active treatment at the end of the
study. From baseline to 24 months 34.5% of the patients changed DMT
due to intolerable adverse effects (13.8%) or disease activity revealed
by clinical and/or radiological examinations (20.7%). 45% (n = 9) of
the patients who changed therapy had a deterioration in EDSS score
(mean change +1.06 points, range 0.5–2.0 points), 20% (n = 4)
showed an improvement (mean change −0.63 points, range 0.5–1.0
points), and 35% (n= 7) were clinically stable (Table 1). 65% (n= 13)
escalated therapy from “active” to “highly-active”, 15% (n = 3) were
treatment naïve at the start of the study, and 20% (n = 4) changed to
another “highly-active” therapy.
3.3. Cognitive performance (BICAMS) from baseline to follow-up
examinations
A total of 27 patients (46.6%) were defined as cognitively impaired
at baseline (i.e. more than one abnormal test score (Dusankova et al.,
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Table 1
Clinical characteristics at baseline, 12 months and 24 months follow-up.
Baseline (N = 58) 12 months (N = 58) 24 months (N = 57)
EDSS, mean (median) 1.35 (1.50) 1.50 (1.50) 1.53 (1.50)
EDSS, change from baseline
Stable,% (N) – 41.4 (24) 40.4 (23)
Worsening,% (N) – 36.2 (21) 40.4 (23)
mean score ∆ – −0.77 points −0.95 points
Improvement,% (N) – 22.4 (13) 19.3 (11)
mean score ∆ – +0.88 points +1.05 points
HADS total score, mean ± SD 7.8 ± 5.9 7.4 ± 5.5 7.5 ± 5.5
Anxiety, mean ± SD 5.1 ± 3.7 4.9 ± 3.6 4.8 ± 3.6
Depression, mean ± SD 2.7 ± 2.9 2.5 ± 2.5 2.7 ± 2.6
FSMC total score, mean ± SD 26.8 ± 19.3 31.5 ± 21.0* 30.6 ± 20.3*
Cognitive, mean±SD 13.6 ± 10.1 15.8 ± 10.9* 15.3 ± 10.1
Motor, mean± SD 13.2 ± 9.8 15.7 ± 10.4* 15.3 ± 10.7*
SD= standard deviation; EDSS= Expanded Disability Status Scale; HADS= Hospital Anxiety and Depression Scale; FSMC= Fatigue Scale for Motor and Cognitive
Functions.
⁎ Statistically significant change from baseline (p < 0.05).
Fig. 1. Number of patients performing below the cut-off scores on the BICAMS subtests (SDMT 43; CVLT-II 50; BVMT 23) at baseline and at the 24-months follow-up,
and correlations between the test performances at the two time points.
Table 2
Mean raw scores on BICAMS subtests at baseline, 12 months and 24 months.
Baseline 12 months 24 months
Mean SD Mean SD Cohens d⁎⁎ Mean SD Cohens d⁎⁎
SDMT 54.84 10.83 57.28* 11.40 0.41 58.24* 11.34 0.62
CVLT-II 54.29 10.85 57.47* 8.00 0.39 58.10* 10.34 0.53
BVMT-R 27.16 5.59 28.26 5.77 0.20 26.90 5.74 0.06
SD= Standard deviation; SDMT = Symbols Digit Modalities Test; CVLT-II = California Verbal Learning Test, 2nd edition; BVMT-R = Brief Visuospatial Memory
Test, revised.
⁎ Statistically significant change from baseline (p < 0.05).
⁎⁎ Effect size for dependent samples, compared to baseline results.
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2012; Skorve et al., 2019)). 19 patients (32.8%) were impaired on only
one BICAMS test, and 4 patients (6.9%) scored below the cut-off for
impairment on two tests and 4 on all three tests. At the 12 months
follow-up assessment, the number of patients with abnormal test results
was significantly reduced to 16 patients (27.6%, p = 0.01), while 22
patients (37.9%, p = 0.27) were defined as cognitively impaired at the
end of the study (14 patients showed impairment on one subtest, 4
patients on two tests and 4 patients on three tests) There were no sig-
nificant changes in number of patients who showed impairment on
either of the three BICAMS subtests from baseline to 24 months (see
Fig. 1). The mean raw scores for the subtests at baseline, 12 and 24
months are presented in Table 2. Both the SDMT and the CVLT-II scores
were significantly improved from baseline to 12 months (p= 0.003 and
p= 0.004, respectively) and from baseline to 24 months (p< 0.001 for
both tests). The BVMT-R results were overall unchanged from baseline
to the end of the study.
The test-retest correlations between test performances at the dif-
ferent time points were significant at p < 0.001 for all three tests, with
a gradual strengthening of the correlations from baseline through the
first to the second follow-up session, reaching r > 0.75 by 24 months
(Fig. 1).
3.4. Anxiety, depression and fatigue – correlations with cognitive
performances
The prevalence of clinically meaningful anxiety and depression at
baseline (HADS sub-score ≥8) were 14 (24.1%) and 4 (6.9%), respec-
tively, and these numbers remained unchanged at the 24 months
follow-up. Only 13 (22.4%) patients reported some degree of fatigue
(i.e., FSMC total score ≥43) at baseline, and this number increased to
19 patients (32.8%) at 24 months. The corresponding changes in pre-
valence on the cognitive and motor subscales from baseline to the last
follow-up were 22.4% to 29.3%, and 20.7% to 25.9%, respectively. All
changes in the prevalence of anxiety, depression and fatigue at were
statistically non-significant. Correlations between the BICAMS subtests
and the mean HADS and FSMC scores are shown in Tables 3a – 3c. No
correlations were statistically significant at baseline, but there was a
weak to moderate, significant negative correlation between depression,
SDMT and CVLT-II, and between the cognitive fatigue subscale, SDMT
and CVLT-II at 12 months. At 24 months, only the correlations between
depression and CVLT-II, and between the cognitive fatigue subscale and
SDMT remained significant. There were no statistically significant
correlations between BVMT-R and the HADS and FSMC subscales at any
time point.
4. Discussion
To the authors’ knowledge, this is the first longitudinal study where
cognitive performance is measured by repeated testing with the
BICAMS in a sample of newly diagnosed RRMS patients. We found that
the group of MS-patients improved significantly from baseline to the
first follow-up examination, indicating that the effect of being part of a
previous BICAMS assessment is substantial even after 12 months.
Furthermore, large variability in detection of impairment between the
subtests support that all three subtests should be included when
BICAMS is used as a clinical screening tool for cognitive impairment in
patients with MS.
The BICAMS test battery has been validated in several countries and
has become widely accepted as a robust and effective screening tool for
cognitive impairment in MS patients (Corfield and Langdon, 2018). The
aforementioned validation studies have retested healthy controls and
patient samples within the 1–3 week interval recommended to ascertain
test-retest reliability (Benedict et al., 2012). Of the few longitudinal
studies using the BICAMS specifically for evaluation of cognitive
function, one is comparable to the present study regarding sample size,
retest interval and level of physical disability (Frau et al., 2018). Our
patient sample, however, differed by including patients at a younger
age and with a shorter disease duration. Furthermore, our study had a
stronger focus on detection and monitoring of cognitive impairment
within the sample. By this, our longitudinal study presents data that can
be used to evaluate the usability of BICAMS in a routine, clinical
practice.
The mean raw scores on the SDMT and the CVLT-II improved sig-
nificantly from baseline to 12 months and remained stable to the end of
the study, whereas the BVMT-R score showed a mild improvement at 12
months but were overall essentially unchanged from baseline to the end
of the study. Initial improvement in test performance on a first re-test
assessment is known as the practice effect (Ferrer et al., 2004), an effect
that has been explained by factors like increased familiarity with the
content of the test and the test procedure, and may also be related to a
reduced test anxiety. The duration of this effect is, however, not es-
tablished. A recent meta-analysis on this effect on performance on tests
of working memory capacity found that at least 16 months interval was
necessary to eliminate the effect of having performed the same test at
an earlier time point (Scharfen, 2018). Others have shown that this
effect is dependent on the cognitive domain tested (Ferrer et al., 2004).
Therefore, despite the test interval of 12 months, practice effects cannot
be excluded. Studies investigating the practice effects of BICAMS are
needed for better interpretation of the results.
Even patients with impaired BICAMS results at baseline showed
some improvement at follow-up examinations. While almost 50% of the
sample were defined as cognitively impaired at baseline (i.e. abnormal
results on at least on one test), the proportion was reduced to below
30% after 12 months and to below 40% by the end of the study. Most of
Table 3a
Correlations between BICAMS and HADS and FSMC at baseline.
BICAMS subtest HADS sub scores FSMC sub scores
Anxiety Depression Motor Cognitive
r p r p r p r p
SDMT −0.02 0.86 −0.02 0.87 −0.01 0.95 −0.08 0.55
CVLT-II −0.05 0.74 −0.11 0.44 −0.13 0.34 −0.18 0.18
BVMT-R −0.06 0.68 −0.06 0.69 −0.13 0.34 −0.10 0.48
Table 3b
Correlations between BICAMS subtests and HADS- and FSMC sub scores at 12
months.
BICAMS subtest HADS sub scores FSMC sub scores
Anxiety Depression Motor Cognitive
r p r p r p r p
SDMT −0.16 0.23 −0.29* 0.03 −0.2 0.15 −0.35* 0.01
CVLT-II −0.12 0.40 −0.33* 0.02 −0.17 0.22 −0.27* 0.05
BVMT-R 0.09 0.54 −0.15 0.29 −0.09 0.51 −0.2 0.15
Table 3c
Correlations between BICAMS subtests and HADS- and FSMC sub scores at 24
months.
BICAMS subtest HADS sub scores FSMC sub scores
Anxiety Depression Motor Cognitive
r p r p r p r p
SDMT −0.03 0.82 −0.2 0.16 −0.26 0.05 −0.35* 0.01
CVLT-II −0.03 0.83 −0.27* 0.05 −0.18 0.18 −0.24 0.08
BVMT-R 0.16 025 −0.10 0.5 −0.04 0.75 −0.11 0.41
BICAMS = Brief International Cognitive Assessment for Multiple Sclerosis.
SDMT = Symbol Digit Modalities Test. CVLT-II = California Verbal Learning
Test, 2nd edition. BVMT-R = Brief Visuospatial Memory Test, Revised.
HADS = Hospital Anxiety and Depression Scale. FSMC = Fatigue Score for
Motor and Cognitive Function.
⁎ Statistically significant correlation.
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these patients showed impairment on only one test. By this, the num-
bers of patients with a mild impairment at baseline were somewhat
higher than the number reported in a Danish BICAMS validation study
(Marstrand et al., 2020), where approximately 30% of the patients were
classified as cognitively impaired on more than one test. The percen-
tages of patients showing impairment on two or more tests were more
similar across the two studies and the present study contributed by
showing that the patients with a more extended impairment at baseline
remained impaired throughout the study. We suggest that this finding
support previous studies reporting that cognitive impairment shown in
early stages of the disease tends to persist over time (Barbu et al., 2018;
Berard et al., 2018). Among patients with impairment on only one
cognitive test, however, we confirm that the trajectories of change are
much more fluctuating (Katsari et al., 2020). This illustrates the chal-
lenge met by clinicians both regarding identification of patients with
cognitive impairment and when estimating their prognosis and needs
for treatment. Still, we will argue that the quality of the BICAMS gives
the clinician a valid screening instrument. We also suggest that patients
showing impairment on only one subtest should be invited to annual
follow-up assessments to evaluate the risk of a developing a more se-
vere impairment. Patients with impairment on more than one test, on
the other hand, should be considered for a more extensive neu-
ropsychological assessment and rehabilitation. With this routine, results
on the BICAMS subtests may serve as a gatekeeper for the referral of
patients to more extensive examinations with lower capacity and
availability than in most Neurological departments.
The psychometric properties of each of the BICAMS tests is also
worth a comment. A total of 34.5% of the sample showed abnormal test
results on the CVLT-II, while the percentages for BVMT-R and SDMT
were 22.4% and 8.6%, respectively (Skorve et al., 2019). The low
proportion of impairment detected by the SDMT is in contrast to find-
ings presented in other validation studies of BICAMS (Marstrand et al.,
2020; Polychroniadou et al., 2016; Sandi et al., 2015; Sousa et al.,
2018), in which the SDMT was found to be the most sensitive test of
cognitive changes in patients with MS. The Canadian (Walker et al.,
2016) and German (Filser et al., 2018) validation study, however,
found that the BVMT-R identified more patients with cognitive im-
pairment than the other tests, while the Irish study reported results
similar to ours with the CVLT-II identifying impairment in 40% of the
sample (O'Connell et al., 2015). International cut-off scores for the
subtests has been proposed (Beier et al., 2017), but given the large
variability and lack of consensus across studies from different countries
(Smerbeck et al., 2018), national rather than international norms
should be developed. It should be noted that SDMT is often used as a
stand-alone cognitive test in clinical trials and studies of patients with
MS (Benedict et al., 2017; Strober et al., 2019). Recent recommenda-
tions for screening and management of cognitive impairment in clinical
practice also underline the importance of results on the SDMT
(Kalb et al., 2018) as a minimum requirement for cognitive screening.
Our findings do not support this practice because most of the newly
diagnosed MS patients with mild cognitive impairment in our sample
would not have been detected if SDMT was included as the only test of
cognitive function. We therefore strongly argue for the implementation
of the complete BICAMS test battery into clinical practice. Still, it is
important to remember that BICAMS is a screening instrument.
Whenever a clinician is uncertain about the results, the patient should
be referred to a more extensive neuropsychological examination.
The prevalence of clinically meaningful anxiety in this sample was
found to be at the level of the national average reported for MS patients
(Dahl et al., 2009), whereas the prevalence of depression was relatively
low (Korostil and Feinstein, 2007; Patten and Metz, 1997). About 70%
of the participants did not report any fatigue, which is a higher pro-
portion than reported in previous studies (Weiland et al., 2015;
Wood et al., 2013). Similar findings have been reported in the Danish
validation study, which included a sample of patients with similar age
distribution and disease duration as our study (Marstrand et al., 2020).
The lack of significant correlations between results on the BICAMS
subtests and symptoms of anxiety, depression and fatigue at baseline is
also worth a comment. It corresponds to results reported by Golan and
colleagues indicating that mild depression and fatigue do not appear to
impede cognition (Golan et al., 2018). However, when re-assessed after
12 and 24 months, significant negative correlations emerged between
the scores on two of the three BICAMS subtests (SDMT and CVLT-II) and
the depression sub score from HADS and the cognitive subscale from
the FSMC. Thus, our results indicate that HADS and FSMC should be
included as part of the cognitive assessment in follow-up routines of
patients with MS (Portaccio, 2016), and that future longitudinal studies
investigating modulators of associations between emotional and cog-
nitive function are warranted.
More than 95% of the patients in our study received DMT, of whom
approximately 35% changed therapy during the study, 14% did so
because of disease activity. Additional analyses of patients who
changed therapy versus those who did not, revealed similar findings as
the sample as a whole. Given the small number of patients who changed
therapy due to disease activity between test sessions, we do not have
enough power to state whether or not performance on the BICAMS is
influenced by disease activity. In the future, cognitive testing during a
relapse could yield interesting insight into fluctuations in cognitive
performance over the disease course and its response to disease mod-
ifying therapy.
Almost 90% of the patients were employed at the start of the follow-
up, and more than 80% were still employed after two years. These
uplifting numbers may, in part, be due to the relatively low mean age of
the participants, their short disease duration, and low level of physical
disability, combined with the use of DMT. Increased focus on cognitive
impairment in MS may also have led the patients to request work place
customization, promoting an increase or at least a stable work capacity
at the individual level. Data was not collected to investigate this im-
portant issue, and further studies on the effect of participation in clin-
ical studies on the patients’ self-awareness, coping strategies and mo-
tivation should be performed.
A limitation of the study is the lack of control for demographic
variables, but we considered the cohort to be too small in the present
study to yield sufficient statistical power. Furthermore, we did not in-
tend to make predictions on an individual level, but rather investigate
overall projections over time for a group of individuals with newly
diagnosed MS. A group of healthy controls followed over the same time
period would have improved the impact of our results, but longitudinal
data from the control group was not available for the present study.
Although our cohort is relatively small, it is well-defined with almost no
loss of follow-ups so far. Hopefully, we will be able to run 5 and 10 year
follow-up studies to determine how well their performances on cogni-
tive tests correspond with results shown in other cohorts.
5. Conclusions
The BICAMS identified almost 50% of a newly diagnosed sample of
patients with MS as cognitively impaired on at least one test measure at
baseline. Abnormal results on more than one test seemed to predict
persistent cognitive impairment, while a more fluctuating develop-
mental pathway was shown by the patients with mild symptoms at
baseline, i.e., impairment on only one of the three BICAMS tests. Both
this within-subject variability in cognitive function and the significant
improvement from baseline to the first follow-up due to practice effects,
illustrates the importance of including repeated assessments of cogni-
tive function in patients with MS. The rather large differences in the
detection rate on the three subtests also highlights the value of in-
cluding all three subtests when using the BICAMS as a screening in-
strument. The symptoms of depression, anxiety and fatigue were mild
in the present sample, and although this did not seem to impede cog-
nition in the present study, we still will recommend including assess-
ment of anxiety, depression and fatigue when screening for cognitive
E. Skorve, et al. Multiple Sclerosis and Related Disorders 46 (2020) 102577
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impairment in patients with MS.
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